Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium
Year: 2021
Type: article
Source: Cytotherapy
Authors: K.J. Curran, V.A. Fabrizio, A. Mauguen, J.J. Boelens, C. Baggott, S. Prabhu, H. Placenta, C.L. Phillips, J. Rossoff, H. Stefanski, J. Talano, A. Moskop, S.P. Margossian, M.R. Verneris, G. Myers, N.A. Karras, P.A. Brown, M. Qayed, M. Hermiston, P. Satwani, C. Krupski, A. Keating, R. Wilcox, C.A. Rabik, V. Chinnabhandar, M. Kunicki, A. Goksenin, C. Mackall, T.W. Laetsch, L.M. Schultz
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Stanford University, The University of Texas Southwestern Medical Center, Cincinnati Children's Hospital Medical Center, Lurie Children's Hospital, University of Minnesota, Medical College of Wisconsin, Boston Children's Hospital, Harvard University, University of Colorado Denver, Children's Mercy Hospital, City Of Hope National Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Emory University, University of California, San Francisco, Columbia University Irving Medical Center, Center for Drug Evaluation and Research
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3161268787